Omics-based Precision Medicine of Epilepsy

Summary

Epilepsy is a major disease of the nervous system (WHO, 2015), as well as the second most common neural disease. It has been recorded that there have been 65 million epilepsy patients all over the world, more than 10 million in China, resulted in high morbidity, high mortality, heavy social and social psychological burden. Due to complex etiology, which genetic playing a large part for 70%-80%, easy to recurrent, as well as various seizure types, a great heterogeneity in clinical manifestation, epilepsy is difficult to treat in general, at least 33% patients. At present, It's still a big challenge in early warning, choice of treatment, efficacy and severe adverse reaction rate, prognosis assessment. Lack of precise diagnosis based genetic and molecular bio-markers for treatment are the main key points. Recently, clinical phenotype classifications of epilepsy have been refined, the exist researches had made a progress in gene mutation mechanism and targeted therapy, which pushed epilepsy being another disease could be precise treated after tumor. It's sure to provide a breakthrough for another neural diseases if epilepsy precise treatment project are successful.

Conditions

• Epilepsy Idiopathic
• Clinical Disease and/or Syndrome
• Gene Mutation

Interventions

OTHER

non

non

Sponsors & Collaborators

• Huashan Hospital

  collaborator OTHER

• Peking University First Hospital

  collaborator OTHER

• Peking University People's Hospital

  collaborator OTHER

• Xiangya Hospital of Central South University

  collaborator OTHER

• First Affiliated Hospital of Chongqing Medical University

  collaborator OTHER

• Children's Hospital of Chongqing Medical University

  collaborator OTHER

• Xuanwu Hospital, Beijing

  collaborator OTHER

• Capital Medical University

  collaborator OTHER

• Second Affiliated Hospital of Guangzhou Medical University

  collaborator OTHER

• Fudan University

  lead OTHER

Principal Investigators

• Wang yi, Dr · leader

Eligibility

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-11-25

Primary Completion

2017-11-26

Completion

2018-07-01

Countries

• China

Study Locations